Detalhe da pesquisa
1.
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
Emerg Microbes Infect
; 13(1): 2284297, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37970736